BioSpace News Archive

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, reported financial results for the full year ended December 31, 2022, and provided a company update.

Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 54,010 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 67,513 shares of Pyxis Oncology’s common stock to three newly hired employees.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) wishes to report that it has filed its interim financial results for the six-month period ended January 31, 2023.

bioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, reported financial results for the three and 12 months ended December 31, 2022.

Belite Bio, Inc announced its financial results for the full-year ended December 31, 2022 and provided a general business update.

ABVC BioPharma, Inc., a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, announced its financial and operating results for the fiscal year ended December 31, 2022.

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001.

AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.